ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 367

In Early Rheumatoid Arthritis Patients with Non-Response to Methotrexate Monotherapy the Change in Multi-Biomarker Disease Activity Score Is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy

Karen Hambardzumyan1, R.J. Bolce2, Saedis Saevarsdottir3, Kristina Forslind4, Ingemar F. Petersson5, Pierre Geborek6, Eric H. Sasso2, David Chernoff2, Scott Cruickshank7 and Ronald F. van Vollenhoven8, 1ClinTRID, the Karolinska Institute, Stockholm, Sweden, 2Crescendo Bioscience Inc., South San Francisco, CA, 3Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Department of Medicine, Karolinska Institute, Stockholm, Sweden, 5Lund University, Lund, Sweden, 6Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 7Scott Cruickshank and Associates, Inc., Santa Barbara, CA, 8Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, biomarkers and rheumatoid arthritis (RA), Clinical Response, Disease Activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity

Session Type: Abstract Submissions (ACR)

Background/Purpose For patients with early RA (eRA), methotrexate (MTX) is recommended as first-line treatment and in non-responders both the addition of conventional non-biological disease modifying anti-rheumatic drug therapy (triple DMARD therapy) and of biological (anti-TNF) therapy are supported by data. Identification of patients with a higher likelihood of responding to one or the other of these options would lead to more personalized medicine and an increased effectiveness of therapy. The objective of this study was to evaluate the change in the multi-biomarker disease activity (MBDA) score (Vectra DA®) during MTX therapy as a predictor of response to subsequent non-biological triple versus biological therapy.

Methods Patients with eRA and DAS28>3.2 entered the Swedish Farmacotherapy (SWEFOT) clinical trial and received MTX monotherapy for 3 months, at which time clinical non-responders (DAS28>3.2) were randomized to receive non-biological triple DMARD therapy (arm A) or anti-TNF (infliximab) therapy with MTX (arm B). For this study, 129 non-responders at month 3 (n=62 from arm A and n=67 from arm B) were analyzed by MBDA score at baseline (BL) and month 3. The assessment of changes in the MBDA score (ΔMBDA) from BL to month 3 as a predictor for response (according to DAS28 and EULAR response criteria) to triple or anti-TNF therapy at year 1 was done by defining small (≤6), moderate (7-20) and large (>20) decreases by tertiles. Small and moderate decreases were combined together (small/moderate) and compared versus large decreases for arms A and B. The proportion of patients in arm A versus arm B with response at year 1 was evaluated by the odds ratio (OR) for patients with small/moderate versus large decreases. Homogeneity of the odds ratios between the two cohorts was assessed by Breslow-Day test.

Results The mean (median) decreases in MBDA score from BL to month 3 for year 1 responders (n=66) and non-responders (n=63) were 12.9 (10) and 10.8 (9), respectively (p=0.431), and Month 3 mean (median) MBDA scores were 47.1 (45) and 50.3 (47), respectively (p=0.336). Of patients who had small/moderate decreases in MBDA score during MTX monotherapy, 43% responded to subsequent triple therapy and 57% responded to anti-TNF (OR=0.577). In contrast, among patients with a large decreases in MBDA score from BL to month 3, 67% responded to subsequent triple therapy and 37% to anti-TNF treatment (OR=3.33). Thus the relative treatment effect of arm A versus arm B differed according to the degree of change in the MBDA score from BL to 3 months (p=0.032). Similarly, good EULAR response was achieved by the majority (67%) of patients from arm A, who had large decrease in MBDA score and also the majority (57%) of patients from arm B, who had small/moderate decrease of the MBDA score.

Conclusion Among patients with early RA who did not achieve low disease activity on MTX monotherapy, those patients with the greatest decrease in MDBA score were more likely to respond to triple therapy whereas patients with lesser decrease of the MBDA score were more likely to respond to anti-TNF therapy. These findings suggest that in MTX non-responders, the changes in MBDA score may help guide subsequent therapy.


Disclosure:

K. Hambardzumyan,
None;

R. J. Bolce,

Crescendo Bioscience,

4,

Crescendo Bioscience,

3;

S. Saevarsdottir,
None;

K. Forslind,
None;

I. F. Petersson,

UCB Pharma, Pfizer, AbbVie,

8;

P. Geborek,
None;

E. H. Sasso,

Crescendo Bioscience,

4,

Crescendo Bioscience,

3;

D. Chernoff,

Crescendo Bioscience,

4,

Crescendo Bioscience,

5;

S. Cruickshank,

Crescendo Bioscience,

5;

R. F. van Vollenhoven,

AbbVie, BMS, GSK, Pfizer, Roche, UCB,

2,

AbbVie, Biotest, BMS, Crescendo, GSK, Janssen, Lilly, Merck, Pfizer, Roche, UCB, Vertex,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-early-rheumatoid-arthritis-patients-with-non-response-to-methotrexate-monotherapy-the-change-in-multi-biomarker-disease-activity-score-is-differentially-associated-with-subsequent-response-to-non-b/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology